Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > pembrolizumab
pembrolizumab
Tuesday 15 March 2016
MK-3475, lambrolizumab, trade name "Keytruda"
| WP |
Pembrolizumab is a humanized antibody used in cancer immunotherapy. It targets the programmed cell death 1 (PD-1) receptor. The drug was initially used in treating metastatic melanoma.
On September 4, 2014 the US Food and Drug Administration (FDA) approved pembrolizumab under the FDA Fast Track Development Program.
It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation.
On October 2, 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer in patients whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents.
Pathology
pembrolizumab-associated colitis
pembrolizumab-associated sarcoidosis